29 30 SOX2 positive pituitary stem cells (PSCs) are specified embryonically and persist throughout 31 life, giving rise to all pituitary endocrine lineages. We have previously shown the activation 32 of the MST/LATS/YAP/TAZ signalling cascade in the developing and postnatal mammalian 33 pituitary. Here, we investigate the function of this pathway during pituitary development and 34 in the regulation of the SOX2 cell compartment. Through loss-and gain-of-function genetic 35 approaches, we reveal that restricting YAP/TAZ activation during development is essential 36 for normal organ size and specification from SOX2+ PSCs. Postnatal deletion of LATS 37 kinases and subsequent upregulation of YAP/TAZ leads to uncontrolled clonal expansion of 38 the SOX2+ PSCs and disruption of their differentiation, causing the formation of non-39 secreting, aggressive pituitary tumours. In contrast, sustained expression of YAP alone results 40 in expansion of SOX2+ PSCs capable of differentiation and devoid of tumourigenic potential. 41 Our findings identify the LATS/YAP/TAZ signalling cascade as an essential component of 42 PSC regulation in normal pituitary physiology and tumourigenesis. 43 44 45 46 47 48 Key words: pituitary stem cell, SOX2, Hippo, YAP, pituitary tumour 49 50 51 52 53 54 55 56 life 1, 2 . The pituitary gland is composed of three parts, the anterior, intermediate and posterior 62 lobes (AL, IL and PL, respectively). The AL and IL contain hormone-secreting cells, which 63 are derived from an evagination of the oral ectoderm expressing SOX2, termed Rathke's 64 pouch (RP). SOX2+ cells, both in the embryonic and adult pituitary, can differentiate into 65 three endocrine cell lineages, which are marked by transcription factors PIT1 (POU1F1) 3 , 66 TPIT (TBX19) 4 and SF1 (NR5A1) 5 , and differentiate into hormone-secreting cells 67 (somatotrophs, lactotrophs, thyrotrophs, corticotrophs, melanotrophs and gonadotrophs, 68
INTRODUCTION 57 58 SOX2 is crucial transcription factor involved in the specification and maintenance of multiple 59 stem cell populations in mammals. Pituitary stem cells express SOX2 and contribute to the 60 generation of new endocrine cells during embryonic development and throughout postnatal 61 each genotype)). We therefore conclude that sustained activation of YAP prevents lineage 141 commitment and is sufficient to maintain the progenitor state during embryonic development. 142 143 Next, we generated embryos null for TAZ and conditionally lacking YAP in the Hesx1 144 expression domain (SFig1B-E). Hesx1 Cre/+ ;Yap fl/fl ;Taz -ldouble mutants were obtained at 145 expected ratios during embryonic stages until 15.5dpc, however the majority of Taz -/mutants 146 with or without compound Yap deletions showed lethality at later embryonic and early 147 postnatal stages 31 (Table 1 ). The developing pituitary gland of Hesx1 Cre/+ ;Yap fl/fl ;Taz -l-148 double mutants appeared largely normal at 13.5dpc by histology (SFig1B). Immunostaining 149 against SOX2 to mark embryonic progenitors and postnatal stem cells did not reveal 150 differences in the spatial distribution of SOX2+ cells between double mutants compared to 151 controls (Hesx1 +/+ ;Yap fl/fl ;Taz +/+ and Hesx1 +/+ ;Yap fl/fl ;Taz +/-) at 13.5dpc, 16.0dpc (SFig1C) or 152 P28, even in regions devoid of both TAZ and active YAP (SFig1D). This suggests that 153 YAP/TAZ are not required for SOX2+ cell specification or survival. Likewise, analysis of 154 commitment markers PIT1and SF1 as well as ACTH to mark the TPIT lineage, did not show 155 any differences between genotypes (SFig1E). Together, these data suggest there is no critical 156 requirement for YAP and TAZ during development for the specification of SOX2+ cells or 157 lineage commitment, but that YAP functions to promote the SOX2 cell identity. pituitaries were macroscopically normal at birth (SFig2A), and showed comparable 169 expression patterns of TAZ, YAP, pYAP to controls lacking Cre, without distinct 170 accumulation of YAP or TAZ (SFig2B). The distribution of SOX2+ cells was comparable 171 between mutants and controls (SFig2B). Normal lineage commitment was evident by 172 immunofluorescence staining for PIT1, TPIT and SF1 at P10 (SFig2C). Mutant animals 173 remained healthy and fertile until P70, at which point pituitaries appeared histologically 174 normal (SFig2D). Since deletion of Mst1/2 at embryonic stages does not affect embryonic or 175 postnatal pituitary development, we conclude these kinases are not critical for YAP/TAZ 176 regulation in the pituitary. 177
178
We next focused on perturbing LATS kinase function, as we have previously shown strong 179 expression of Lats1 in the developing pituitary and postnatal kinase activity in SOX2+ stem 180 cells 28 . However, Hesx1 Cre/+ ;Lats1 fl/fl embryos showed unaffected pituitary development and 181 normal localisation and levels of YAP and TAZ as assessed by immunofluorescence 182 (SFig3A,B) when compared with controls. mRNA in situ hybridisation against Lats2 at P2, 183 revealed abundant Lats2 transcripts upon conditional deletion of Lats1, suggesting a 184 compensatory upregulation of Lats2 in the absence of LATS1 (SFig3C), similar to previous 185 reports of elevated YAP/TAZ signalling inducing Lats2 expression 32 . 186
187
To overcome potential functional redundancy, we deleted both Lats1 and Lats2 in RP. 188
Deletion of Lats2 alone (Hesx1 Cre/+ ;Lats2 fl/fl ), did not reveal any developmental 189 morphological anomalies (SFig3D) and pups were identified at normal Mendelian proportions 190 (Table 2) . Similarly, deletion of any three out of four Lats alleles did not affect pituitary 191 development and were identified at normal ratios, similar to other tissues 33 . Homozygous 192 Hesx1 Cre/+ ;Lats1 fl/fl ;Lats2 fl/fl mutants were identified at embryonic stages at reduced 193
Mendelian ratios and were absent at P0-P2, suggesting embryonic and perinatal lethality 194 ( PIT1, TPIT and SF1 in the double mutant (up to ~ 9%, 4% and 2% respectively, n=3 mutants) 219 compared to controls (~ 50%, 11% and 6%, respectively in controls, n=5) suggesting failure 220 to commit into the three lineages (Fig2D). These data suggest that the LATS/YAP/TAZ axis 221 is required for normal embryonic development of the anterior pituitary and that LATS1/2 222 kinases control proliferation of SOX2+ progenitors and their progression into the three 223 committed lineages. 224
225

Loss of LATS kinases results in carcinoma-like murine tumours 226
Postnatal analysis of Hesx1 Cre/+ ;Lats1 fl/fl pituitaries revealed that by P56, despite developing 227 normally during the embryonic period, all glands examined exhibited lesions of abnormal 228 morphology consisting of overgrowths, densely packed nuclei and loss of normal acinar 229 architecture (n=15). To minimise the likely redundancy by LATS2 seen at embryonic stages, 230
we generated Lats1 mutants additionally haploinsufficient for Lats2 231 In keeping with the morphological evidence of epithelial differentiation, the tumours were 249 positive for cytokeratins using AE1/AE3 (multiple keratin cocktail) (SFig4E). Furthermore, 250 the tumours showed focal morphological evidence of squamous differentiation and this was 251 confirmed by p63 staining (SFig4E). In contrast, the tumours did not show 252 immunohistochemical evidence of adenomas and were negative for typical adenoma markers: 253 the neuroendocrine marker synaptophysin and neuron-specific enolase (SFig4F). The lesions 254 were also negative for chromogranin A, a neuroendocrine granule marker often expressed in 255 clinically non-functioning pituitary adenomas, as well as negative for vimentin, characteristic 256 of spindle cell oncocytoma (SFig4F). Moreover, immunostaining against PIT1, TPIT and SF1 257 showed only sparse positive cells within the lesions, suggesting lack of commitment into 258 endocrine precursors and supporting the undifferentiated nature of the tumour cells (Fig3D). 259
Consistent with a tumourigenic phenotype, and role for LATS1 genomic stabilisation 37 , 260 staining for gamma-H2A.X detected elevated DNA damage in cells of the mutant pituitaries Loss of LATS1 is sufficient to drive deregulation of SOX2+ pituitary stem cells, generating 288 highly proliferative non-functioning tumours with features of carcinomas. 289
290
YAP expression is sufficient to activate pituitary stem cells. 291
Conditional deletion of LATS1/2 kinases in the pituitary has revealed how these promote an 292 expansion of SOX2+ve stem cells in the embryonic and postnatal gland at the expense of 293 differentiation. To establish if this effect was mediated through YAP alone, we used the 294 tetracycline-controlled conditional YAP-TetO system to promote YAP (S127A) protein levels 295 in postnatal pituitaries of Hesx1 Cre/+ ;R26 rtTA/+ ;Col1a1 tetO-Yap1/+ mice. We treated YAP-TetO 296 animals with doxycycline from P21 to P105 (12 week treatment, Fig5A). We did not observe 297 the formation of tumours at any stage analysed (n=12, SFig6A). Similarly, we did not observe 298 the formation of lesions when treating from P5. This is in contrast with the unequivocal 299 tumour formation observed in Sox2 CreERT2/+ ;Lats1 fl/fl ;Lats2 fl/+ mice. Elevation of YAP protein 300 levels was confirmed following three weeks of doxycycline treatment (P42), displaying 301 patchy accumulation, likely a result of genetic recombination efficiencies (Fig5B). Consistent 302 with pathway activation, there was robust elevation in the expression of transcriptional targets 303 Cyr61 and Ctgf following treatment (SFig6B) and there was no elevation in phosphorylated 304
Immunofluorescence against SOX2 demonstrated a significant increase in the number of 307 SOX2+ cells as a proportion of the anterior pituitary (Fig5B,F; 18.0% compared to 12.1% in 308 controls, P=0.0014), a finding recapitulated by SOX9 that marks a subset of the SOX2 309 population (Fig5B). This increase in the percentage of SOX2+ cells was maintained at all 310 stages analysed (Fig5F) and did not affect the overall morphology of the pituitary. At P42 we 311 observed a significant increase in proliferation among the SOX2+ pituitary stem cells from 312 3% in controls to 15% in mutants (P=0.027). SOX2+ cells make up 11% of all cycling cells 313 (Ki-67%) in normal pituitaries, however in mutants this increased to 24%, suggesting a 314 preferential expansion of the SOX2+ population, rather than an overall increase in 315 proliferation (Fig5C). No additional marked differences were observed in samples analysed 316 at P63 (6 weeks of treatment, n=3), however longer treatment (P21 to P105) resulted in 317 sporadic regions of expanded SOX2+ cells (SFig6C). These regions did not express the 318 commitment marker PIT1 and were identifiable by haematoxylin/eosin staining. In contrast to 319 tumour lesions generated following loss of LATS kinases, these were not proliferative, were 320 positive for pYAP and did not accumulate high levels of YAP/TAZ (n=6 lesions). Together 321 these results suggest that the sustained expression of constitutive active YAP can activate the 322 proliferation of SOX2 stem cells, but in contrast to deletion of LATS1, this alone is not 323 oncogenic. 324
325
To establish if the expansion of pituitary stem cells following forced expression of YAP is 326 reversible, we administered doxycycline to YAP-TetO animals for three weeks (P21 to P42) 327 by which point there is a robust response, followed by doxycycline withdrawal for three 328 weeks (until P63) to allow sufficient time for YAP levels to return to normal (scheme Fig5D). 329
Immunofluorescence against total YAP protein confirmed restoration of the normal YAP 330 expression pattern and levels after recovery (Fig5E) Loss of LATS1 heterozygosity has been reported in a range of human tumours 39, 40, 41, 42 363 leading to an increase in YAP/TAZ protein levels. Previous global deletion of Lats1 in mice 364 resulted in a variety of soft tissue sarcomas and stromal cell tumours 43 . The anterior lobe of 365 these animals appeared hyperplastic with poor endocrine cell differentiation leading to 366 combined hormone deficiencies, but the presence of tumours was not noted. We report that 367 loss of Lats1 alone is sufficient to drive anterior and intermediate lobe tumour formation. This 368 phenotype is accelerated following additional deletion of one copy of Lats2. Phenotypically 369 identical tumour lesions were generated when the genetic deletions were carried out 370 embryonically in the RP, or at postnatal stages. Interestingly, tissue-specific loss of Mst1 and 371
Mst2, which regulate LATS activation in other tissues 44 , did not lead to any pituitary defects. 372
Similar situations have been reported in other organs where LATS are functioning 44 . These 373 data suggest that alternative regulation on LATS kinases is likely to be active in the pituitary. 374
The resulting non-secreting tumours in our mouse models are composed predominantly of 375 By dissecting the downstream requirement for YAP in pituitary regulation by the 392 LATS/YAP/TAZ axis, we found that expression of constitutively active YAP (S127A) is 393 sufficient to push SOX2+ pituitary stem cells into an activated state, leading to expansion of 394 the stem cell cohort. YAP has previously been indicated to promote the stem cell state in 395 other tissues, e.g. pancreas neurons mammary glands 49 . However, this does not fully 396 recapitulate the LATS deletion phenotypes, as it did not lead to the formation of tumours 397 during the time course of YAP activation (12 weeks). However, the temporal control of 398 expressing the mutation is critical, as seen in other tumour models 50 . Instead, the findings 399 identify an isolated role for YAP in promoting the expansion of the SOX2+ stem cell pool 400 and restoring their proliferative potential to levels akin to the most active state during 401 postnatal pituitary growth. Activity of YAP/TAZ is reduced in dense tissues, resulting in a 402 decrease in stemness. One mechanism through which this is achieved is by crosstalk with 403 other signaling pathways regulating stem cell fate 51, 52 . For example, a decrease in YAP/TAZ 404 activity removes inhibition on Notch signalling, resulting in higher levels of differentiation 405 and a drop in stem cell potential 53 . In the pituitary, Notch plays a role in the maintenance of 406 the SOX2 stem cell compartment and is involved in regulating differentiation 54, 55, 56, 57 . The 407 downstream mechanisms of YAP action on SOX2+ pituitary stem cells, as well as the likely 408 crosstalk with other signalling pathways remain to be explored. 409
410
In summary, our findings highlight roles for LATS/YAP/TAZ in the regulation of pituitary 411 stem cells, where fine-tuning of their expression can make the difference between 412 physiological stem cell re-activation and tumourigenesis, of relevance to other organs. We 413 reveal this axis is involved in the control of cell fate commitment, regulation of regenerative 414 potential and promotion of tumourigenesis. These findings can aid in the design of treatments 415 against pituitary tumours and in regenerative medicine approaches targeting the regulation of 416 endogenous stem cells. Sections were selected for the appropriate axial level, to include Rathke's pouch or pituitary, 478
as described previously 28 . The RNAscope 2.5 HD Reagent Kit-RED assay (Advanced Cell 479
Diagnostics) was used with specific probes: Ctgf, Cyr61, Lats2 (all ACDBio). 480
481
H&E staining 482
Sections were dewaxed in histoclear and rehydrated through graded ethanol series from 100% 483 to 25% ethanol, then washed in distilled H 2 O. Sections were stained with Haematoxylin QS 484 (Vector #H3404) for 1 minute, and then washed in water. Slides were then stained in eosin in 485 70% ethanol for 2 minutes and washed in water. Slides were dried and coverslips were 486 mounted with VectaMount permanent mounting medium (Vector Laboratories H5000). 487 488
Immunofluorescence and immunohistochemistry 489
Slides were deparaffinised in histoclear and rehydrated through a descending graded ethanol 490 series. Antigen retrieval was performed in citrate retrieval buffer pH6.0, using a Decloaking 491
Chamber NXGEN (Menarini Diagnostics) at 110°C for 3mins. Tyramide Signal 492 Amplification (TSA) was used for staining using antibodies against YAP (1:1000, Cell 493
Signaling #4912S), pYAP (1:1000, Cell Signaling #4911S), TAZ (1:1000, Atlas Antibodies 494 #HPA007415) and SOX2 (1:2000, Abcam ab97959) with EMCN (1:1000, Abcam ab106100) 495 staining as follows: sections were blocked in TNB (0.1M Tris-HCl, pH7.5, 0.15M NaCl, 496 0.5% Blocking Reagent (Perkin Elmer FP1020)) for 1 hour at room temperature, followed by 497 incubation with primary antibody at 4C overnight, made up in TNB. Slides were washed three 498 times in TNT (0.1MTris-HCl pH7.5, 0.15M NaCl, 0.05% Tween-20) then incubated with 499 secondary antibodies (biotinylated anti-rabbit (1:350 Abcam ab6720) and anti-Rat Alexa 500
Fluor 555 (1:300, Life Technologies A21434) for 1 hour at room temperature and Hoechst 501
(1:10000, Life Technologies H3570). Slides were washed again then incubated in ABC 502 reagent (ABC kit, Vector Laboratories PK-6100) for 30 mins, followed by incubation with 503 TSA conjugated fluorophore (Perkin Elmer NEL753001KT) for ten minutes. Slides were 504 washed and mounted with VectaMount (Vector Laboratories H1000). 505
For regular immunofluorescence sections were blocked in blocking buffer (0.15% glycine, 506 2mg/ml BSA, 0.1% Triton-X in PBS), with 10% sheep serum (donkey serum for goat SOX2 507 antibody) for 1 hour at room temperature, followed by incubation with primary antibody at 508 (1:1000, Abcam ab2893), Vimentin (1:300, Cell Signaling #5741), Caspase (1:300, Cell 514
Signaling #9661S). Slides were washed in PBST then incubated with secondary antibodies 515
for 1 hour at room temperature. Appropriate secondary antibodies were incubated in blocking 516 buffer for 1 hr at room temperature (biotinylated anti-rabbit (1:350, Abcam ab6720), 517 biotinylated anti-mouse (1:350, Abcam ab6788), anti-chicken 488 (1:300, Life Technologies 518 A11039), anti-goat 488 (1:300, Abcam ab150133). Slides were washed again using PBST and 519 incubated with fluorophore-conjugated Streptavidin (1:500, Life Technologies S21381 or 520 S11223) for 1 hour at room temperature, together with Hoechst (1:10000, Life Technologies 521 H3570). Slides were washed in PBST and mounted with VectaMount (Vector Laboratories, 522 H1000 Wholemount images were taken with a MZ10 F Stereomicroscope (Leica Microsystems), 538 using a DFC3000 G camera (Leica Microsystems). For bright field images, stained slides 539
were scanned with Nanozoomer-XR Digital slide scanner (Hamamatsu) and images processed 540 using Nanozoomer Digital Pathology View. Fluorescent staining was imaged with a TCS SP5 541 confocal microscope (Leica Microsystems) and images processed using Fiji 63 . 542 543
Quantifications of cell number 544
Cell counts were performed manually using Fiji cell counter plug-in; 5-10 fields were counted 545 per sample, totalling over 1500 nuclei, across 3-5 pituitaries. Statistical analyses and graphs 546 were generated in GraphPad Prism (GraphPad Software). Immunofluorescence staining for LHX3 to mark anterior pituitary tissue and SOX2 to mark 564 pituitary progenitors shows the persistence of SOX2 protein in lateral regions of the gland in 565 YAP-TetO mutants (arrowheads) when they have lost SOX2 expression in controls (arrows) 566 (magnified boxed region in SOX2, corresponding to dashed box in LHX3). D. 567
Immunofluorescence staining for lineage-committed progenitor markers PIT1, TPIT and SF1 568 reveals very few cells expressing commitment markers in YAP-TetO compared to control. 569
Scale bars 100µm, 50µm in magnified boxed regions in C. See Also Supplementary Figure 1 . 
